{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-066700","form_type":"8-K","ticker":"HOOK","cik":"0001760542","company_name":"HOOKIPA Pharma Inc.","filed_at":"2023-05-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.430881+00:00","generated_at":"2026-06-14T10:40:18.151327+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"HOOKIPA Phase 2 HB-200 data: 43% ORR with pembrolizumab vs 19% historical; pivotal trial planned for 2024","bullets":["HB-200 + pembrolizumab showed 43% objective response rate (6/14 patients) in 1st-line HPV16+ head/neck cancer, doubling pembrolizumab alone.","Median overall survival of 14.2 months in heavily pre-treated monotherapy cohort (n=11, median follow-up 12.8 months).","Safety: 7% serious adverse events related to HB-200; 2% discontinuation rate across 132 patients.","Company preparing to start pivotal trial of HB-200 + pembrolizumab in 1st-line setting in 2024.","HB-200 induced rapid, sustained T-cell responses for at least 8 months associated with clinical benefit."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-066700","json":"https://secwatch.observer/filing/0001104659-23-066700.json","markdown":"https://secwatch.observer/filing/0001104659-23-066700.md","text":"https://secwatch.observer/filing/0001104659-23-066700.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1760542/000110465923066700/0001104659-23-066700-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1760542/000110465923066700/tm2317399d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T10:40:18.151327+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}